Modern Approaches in Lung Cancer Management from Herbal Nanomedicine to Artificial Intelligence

Year : 2026 | Volume : 16 | 02 | Page :
    By

    Harshala K. Patil,

  • Akash S. Jain,

  • Divakar R. Patil,

  • Azam Z. Shaikh,

  • Sameer R. Shaikh,

  • Priya N. Chaudhari,

  • S. P. Pawar,

  1. Student of Final Year B. Pharmacy, Department of Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  2. Asssistant Professor, Department of Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  3. Asssistant Professor, Department of Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  4. Asssistant Professor, Department of Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  5. Asssistant Professor, Department of Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  6. Asssistant Professor, Department of Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  7. Principle, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, india

Abstract

Lung cancer continues to be a major global health concern and one of the leading causes of cancer-related mortality worldwide. Despite significant advancements in therapy, there is still a pressing need for safer and more effective therapeutic alternatives; problems such drug resistance, side effects, metastasis, and recurrence continue to impact patient outcomes and quality of life. Examining current advancements in the use of herbal drug-loaded nanoparticles as a novel approach to lung cancer treatment is the goal of this review. A comprehensive analysis of various nanoparticle-based drug delivery systems is given, emphasizing how they can enhance the solubility, bioavailability, and targeted administration of herbal constituents. In order to increase the precision and efficacy of lung cancer treatment, the review also assesses the biomarkers used for targeted therapy and looks at how novel personalized treatment approaches like wearable electronic patches, robotics-assisted interventions, smartphone-enabled therapies, AI-driven diagnostics, and lung-on-a-chip technologies can be combined. In conclusion, the future of lung cancer treatment could undergo significant changes as a result of the integration of nanotechnology and personalized medicine.

Keywords: Lung Cancer, Herbal Medicine, Nanoparticles, Artificial Intelligence, Lung Cancer Biomarkers.

How to cite this article:
Harshala K. Patil, Akash S. Jain, Divakar R. Patil, Azam Z. Shaikh, Sameer R. Shaikh, Priya N. Chaudhari, S. P. Pawar. Modern Approaches in Lung Cancer Management from Herbal Nanomedicine to Artificial Intelligence. Research and Reviews: A Journal of Pharmacology. 2026; 16(02):-.
How to cite this URL:
Harshala K. Patil, Akash S. Jain, Divakar R. Patil, Azam Z. Shaikh, Sameer R. Shaikh, Priya N. Chaudhari, S. P. Pawar. Modern Approaches in Lung Cancer Management from Herbal Nanomedicine to Artificial Intelligence. Research and Reviews: A Journal of Pharmacology. 2026; 16(02):-. Available from: https://journals.stmjournals.com/rrjop/article=2026/view=242614


References

1. Ji, Y.; Zhang, Y.; Liu, S.; Li, J.; Jin, Q.; Wu, J.; Duan, H.; Liu, X.; Yang, L.; Huang, Y. The epidemiological landscape of lung cancer: Current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022. J. Natl. Cancer Cent.2025, 5, 278–286.
2. Quadros, M.; Goyal, M.; Chauhan, G.; Gadhave, D.; Gupta, V.An Inhaled Nanoemulsion Encapsulating a Herbal Drug for Non-Small Cell Lung Cancer (NSCLC) Treatment. Pharmaceutics 2025, 17, 540.
3. Valeria Maria de Oliveira Cardoso, Maria Julia Bistaffa, Raquel Gonzalez Sterman, Lorena Leticia Peixoto de Lima, Gustavo Silveira Toldo, Juliana Cancino-Bernardi, and Valtencir ZucolottoNanomedicine Innovations for Lung Cancer Diagnosis and TherapyACS Appl. Mater. Interfaces 2025, 17, 13197−13220
4. Raahulan Sivarajakumar, Dhamini Mallukaraj, Madhurya Kadavakollu, Niveditha Neelakandan, Sandhya Chandran, Saravanan Bhojaraj, Veera Venkata Satyanarayana Reddy Karri Nanoparticles for the Treatment of Lung Cancers Journal of Young Pharmacists, Vol 10, Issue 3, Jul-Sep, 2018
5. Abdulridha, M.K.; Al-Marzoqi, A.H.; Al-Awsi, G.R.L.; Mubarak, S.M.; Heidarifard, M.; Ghasemian, A. Anticancer effects of herbal medicine compounds and novel formulations: A literature review. J. Gastrointest. Cancer 2020, 51, 765–773
6. Jie Huang, MM1* , Jia-Xin Li, PhD1* , Lin-Rui Ma, MM1, Dong-Han Xu, PhD1,Peng Wang, PhD1, Li-Qi Li, MM1, Li-Li Yu, PhD1, Yu Li, PhD1, Run-Ze Li,Ph D2, Hao Zhang, PhD1, Yu-Hong Zheng, MM1, Ling Tang, PhD3,4,5, and Pei- Yu Yan, PhD1 Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the in the Future Volume 21: 1–13Submitted September 11, 2022.
7. Lin, S.R.; Chang, C.H.; Hsu, C.F.; Tsai, M.J.; Cheng, H.; Leong, M.K.; Sung, P.J.; Chen, J.C.; Weng, C.F. Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. Br. J. Pharmacol. 2020, 177, 1409–1423.
8. Khosravifarsani M, Tolouian R, Yadollahifarsani S, Soleimani P, Sarazen M, Mostafizi P, Tolouian A, Philip AK, Golestani Hotkani Z. Medical plants for lung cancer: an overview of current knowledge. Immunopathol Persa. 2023; 9(1):e38455.
9. Arghavan Memarzia1,2 | Saeideh Saadat1,3 | Fereshteh Asgharzadeh2 | Sepide Behrouz |Gert Folkerts | Mohammad Hossein Boskabady,Therapeutic effects of medicinal plants and their constituents on lung cancer, in vitro, in vivo and clinical evidenceJ Cell Mol Med. 2023;27:2841–2863
10. Chavda, V.P.; Patel, A.B.; Mistry, K.J.; Suthar, S.F.; Wu, Z.X.; Chen, Z.S.; Hou, K. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: Recent progress and future challenges. Front. Oncol. 2022, 12, 867655.
11. Javed Ahmad1,Sohail Akhter, Md Rizwanullah1,Saima Amin1,Mahfoozur Rahman4,Mohammad Zaki Ahmad5,Moshahid Alam Rizvi6,Mohammad A Kamal7 ,Farhan Jalees
12. Ahmad1, 2Nanotechnology-based inhalation treatments for lung cancer Nanotechnology, Science and Applications 2015:8 55–66.
13. Taioli, E.; Flores, R.M.; Abdelhamid, A.; Untalan, M.; Ivic-Pavlicic, T.; Tuminello, S. Antibiotic use and survival in late-stage non-small cell lung cancer patients treated with chemo-immunotherapy. JTO Clin. Res. Rep. 2024, 5, 100710.
14. Keisuke Onoi, Yusuke Chihara, Junji Uchino * , Takayuki Shimamoto, Yoshie Morimoto,Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada and Koichi Taka Yama Immune Checkpoint Inhibitors for Lung Cancer Treatment: J. Clin. Med. 2020, 9, 1362.
15. Rotow, J.; Bivona, T.G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 2017, 17, 637–658.
16. Batra U and Nathany S (2025) Biomarker testing in lung cancer: from bench to bedside. Oncol. Rev. 18:1445826.
17. Ramalingam, S.S.; Vansteenkiste, J.; Planchard, D.; Cho, B.C.; Gray, J.E.; One, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y. Chewaskulyong, B.; et al. Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N. Engl. J. Med. 2020, 382,41–50.
18. Jia, Y.; Yun, C.-H.; Park, E.; Ercan, D.; Manuia, M.; Juarez, J.; Xu, C.; Rhee, K.; Chen, T.; Zhang, H.; et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 2016, 534, 129–132.
19. Meador, C.B.; Sequist, L.V.; Piotrowska, Z. Targeting Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discover. 2021, 11, 2145–2157.
20. Cho, J.H.; Lim, S.H.; An, H.J.; Kim, K.H.; Park, K.U.; Kang, E.J.; Choi, Y.H.; Ahn, M.S.; Lee, M.H.; Sun, J.-M.; et al. Osimertinib for Patients with Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J. Clin. Oncol. 2020, 38, 488–495.
21. Alice T. Shaw and Jeffrey A. Engelman ALK in Lung Cancer: Past, Present, and Future J Clin Oncol 31:1105-1111.
22. Giandomenico Roviello1 & Alberto D’Angelo2 & Marianna Sirico3,4 & Matteo Pittacolo5 & Felipe Umpierre Conter5 & Navid Sobhani5 Advances in anti-BRAF therapies for lung cancer Investigational New Drugs (2021) 39:879–890.
23. Ravi Salgia MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale 0.1158/1535-7163.MCT-16-0472.
24. Parvez, A.; Choudhary, F.; Mudgal, P.; Khan, R.; Qureshi, K.A.; Farooqi, H.; Aspatwar, A. PD-1 and PD-L1: Architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front. Immunol. 2023, 14, 1296341.
25. Hellmann, M.D.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S.-W.; Carcereny Costa, E.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2019, 381, 2020–2031.
26. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996; 73: 931–934.
27. Niu, Z.; Jin, R.; Zhang, Y.; Li, H. signalling pathways and targeted therapies in lung squamous cell carcinoma: Mechanisms and clinical trials. Signal Transduct. Target. Ther. 2022, 7, 353.
28. Jiaqi Feng2†, Pengpeng Zhang2†, Dingli Wang2, Yuting Li1 and Jiaxiong Tan3 New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology Feng et al. Biomarker Research (2024) 12:136.
29. Carita, A.C.; Eloy, J.O.; Chorilli, M.; Lee, R.J.; Leonardi, G.R. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr. Med. Chem. 2018, 25, 606–635.
30. Yao, Y.; Zhou, Y.; Liu, L.; Xu, Y.; Chen, Q.; Wang, Y.; Wu, S.; Deng, Y.; Zhang, J.; Shao, A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci 2020, 7, 193.
31. Woodman, C.; Vundu, G.; George, A.; Wilson, C.M. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. In Seminars in Cancer Biology; Academic Press: Cambridge, MA, USA, 2021; Volume 69, pp. 349–364.
32. Chen, Y.; Yang, J.; Fu, S.; Wu, J. Gold nanoparticles as radiosensitizers in cancer radiotherapy. Int. J. Nanomed. 2020, 15, 9407–9430.
33. Zhou, M.; Liang, S.; Liu, D.; Ma, K.; Yun, K.; Yao, J.; Peng, Y.; Hai, L.; Zhang, Q.;Wang, Z. Manganese-Enriched Zinc Peroxide Functional Nanoparticles for Potentiating Cancer Immunotherapy. Nano Lett. 2023, 23, 10350–10359.
34. Kanipandian, N.; Li, D.; Kannan, S. Induction of intrinsic apoptotic signaling pathway in A549 lung cancer cells using silver nanoparticles from Gossypium hirsutum and evaluation of in vivo toxicity. Biotechnol. Rep. 2019, 23, e00339.
35. Singh, S.; Goel, T.; Singh, A.; Chugh, H.; Chakraborty, N.; Roy, I.; Tiwari, M.; Chandra, R. Synthesis and characterization of Fe3O4@ SiO2@ PDA@ Ag core–shell nanoparticles and biological application on human lung cancer cell line and antibacterial strains. Artif. Cells Nanomed. Biotechnol. 2024, 52, 46–58.
36. Bonifacio, B.V.; da Silva, P.B.; Ramos, M.A.D.S.; Negri, K.M.S.; Bauab, T.M.; Chorilli, M. Nanotechnology-based drug delivery systems and herbal medicines: A review. Int. J. Nanomed. 2014, 9, 1–15.
37. El-Far SW, Helmy MW, Khattab SN, et al. Phytosomal bilayer-enveloped casein micelles for codelivery of monascus yellow pigments and resveratrol to breast cancer. Nanomedicine. 2018; 13:481–499.
38. Chen Z, Zhu Q, Qi J, et al. Sustained and controlled release of herbal medicines: the concept of synchronized release. Int J Pharm. 2019; 560:116–125.
39. Kabary DM, Helmy MW, Elkhodairy KA, et al. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma. Colloids Surf B Biointerfaces. 2018; 169:183–194.
40. Abdelmoneem M, Elnaggar M, Hammady R, et al. Dual-Targeted lactoferrin shell-oily core nanocapsules for synergistic targeted/ herbal therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2019; 11:26731–26744.
41. Diksha Sharma *, Lakshay and Kapil Kumar Verma Observing nanotechnology in herbal medicine World Journal of Biology Pharmacy and Health Sciences, 2024, 20(01), 176–191.
42. Zhang Y-Q, Shen Y, Liao -M-M, et al. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms. Nanomedicine. 2019; 15(1):86–97.
43. Said-Elbahr R, Nasr M, Alhnan MA, et al. Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer. Eur J Pharm Biopharm. 2016; 103:1–12.
44. Kumkoon, T.; Srisaisap, M.; Boonserm, P. Biosynthesized silver nanoparticles using Morus alba (white mulberry) leaf extract as potential antibacterial and anticancer agents. Molecules 2023, 28, 1213.
45. Panek-Krzys´ko, A.; Stompor-Gora˛cy, M. The pro-health benefits of morusin administration—an update review. Nutrients 2021, 13, 3043.
46. Zhang, J.; Liu, X.; Zhang, G.;Wu, J.; Liu, Z.; Liu, C.;Wang, H.; Miao, S.; Deng, L.; Cao, K.; et al. To explore the effect of Kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking. Front. Pharmacol. 2023, 14, 1148171.
47. Ma˛czka, W.; Win´ ska, K.; Grabarczyk, M. One hundred faces of geraniol. Molecules 2020, 25, 3303.
48. Song, X.; Tan, L.; Wang, M.; Ren, C.; Guo, C.; Yang, B.; Ren, Y.; Cao, Z.; Li, Y.; Pei, J. Myricetin: A review of the most recent research. Biomed. Pharmacother. 2021, 134, 111017.
49. Paudel, K.R.; Mehta, M.; Yin, G.H.S.; Yen, L.L.; Malyla, V.; Patel, V.K.; Panneerselvam, J.; Madheswaran, T.; MacLoughlin, R.; Jha, N.K.; et al. Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro. Environ. Sci. Pollut. Res. 2022, 29, 46830–46847.
50. Wu, Y.Y.; Zhang, J.H.; Gao, J.H.; Li, Y.S. Aloe-emodin (AE) nanoparticles suppresses proliferation and induces apoptosis in human lung squamous carcinoma via ROS generation in vitro and in vivo. Biochem. Biophys. Res. Commun. 2017, 490, 601–607.
51. Alshehri, S.; Bukhari, S.I.; Imam, S.S.; Hussain, A.; Alghaith, A.F.; Altamimi, M.A.; AlAbdulkarim, A.S.; Almurshedi, A. Formulation of Piperine-Loaded Nanoemulsion: In Vitro Characterization, Ex Vivo Evaluation, and Cell Viability Assessment. ACS Omega 2023, 8, 22406–22413.
52. Tripathi, A.K.; Ray, A.K.; Mishra, S.K. Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: Evidence from clinical trials. Beni-Suef Univ. J. Basic Appl. Sci. 2022, 11, 16.
53. Chen, B.H.; Hsieh, C.H.; Tsai, S.Y.; Wang, C.Y.; Wang, C.C. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci. Rep. 2020, 10, 5163.
54. Vivek P. Chavda1, Aayushi B. Patel2†‡, Kavya J. Mistry2†, Suresh F. Suthar2†, Zhuo-Xun Wu3, Zhe-Sheng Chen3 and Kaijian Hou Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer Frontiers in Oncology March 2022 | Volume 12.
55. Masika Anna Mahinda Biopolymer-Based Nanocarriers for Synergistic Delivery of Anti-Obesity and Anticancer Phytochemicals IAA Journal of Biological Sciences 13(2):95-102, 2025.
56. Raahulan Sivarajakumar, Dhamini Mallukaraj, Madhurya Kadavakollu, Niveditha Neelakandan, Sandhya Chandran, Saravanan Bhojaraj, Veera Venkata Satyanarayana Reddy Karri Nanoparticles for the Treatment of Lung Cancers J Young Pharm, 2018; 10(3): 276-281.
57. Parvin, N.; Aslam, M.; Joo, S.W.; Mandal, T.K. Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. Molecules 2025, 30, 3177.
58. Chris Oerlemans & Wouter Bult & Mariska Bos & Gert Storm & J. Frank W. Nijsen & Wim E. Hennink Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release Pharm Res (2010) 27:2569–2589.
59. Madumani Amararathna1, Kerry Goralski2, David W. Hoskin3,4, H. P. Vasantha Rupasinghe Pulmonary Nano-Drug Delivery Systems for Lung Cancer: Current Knowledge and Prospects Amararathna M, Goralski K, Hoskin DW, Rupasinghe HPV. Pulmonary Nano-Drug Delivery Systems for Lung Cancer: Current Knowledge and Prospects. J Lung Health Dis (2019) 3(2): 11-28.
60. Mall, J.; Naseem, N.; Haider, M.F.; Rahman, M.A.; Khan, S.; Siddiqui, S.N. Nanostructured Lipid Carriers as a Drug Delivery System: A Comprehensive Review with Therapeutic Applications. Intell. Pharm. 2024, in press.
61. Saniha Ajith a, Fares Almomani a,*, Abdelbary Elhissi b, Ghaleb A. Husseini Nanoparticle-based materials in anticancer drug delivery: Current and future prospects Heliyon 9 (2023) e21227.
62. Mueller RH, Maeder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000; 50:161-77.
63. Manivannan Rangasamy Nano Technology Journal of Applied Pharmaceutical Science 01 (02); 2011: 08-16.
64. NAGAVARMA B V N, HEMANT K.S.YADAV*, AYAZ A, VASUDHA L.S, SHIVAKUMAR H.G DIFFERENT TECHNIQUES FOR PREPARATION OF POLYMERIC NANOPARTICLES Asian Journal of Pharmaceutical and Clinical Research Vol 5, Suppl 3, 2012 16-23.
65. York P. Strategies for particle design using supercritical fluid technologies. Pharm Sci Technol Today 1999; 2:430–40.
66. Sahni JK, Baboota S, Ali J. Promising Role of Nanopharmaceuticals in Drug Delivery. Pharma Times 2011; 43:16-8.
67. George Stain Nanoparticle Synthesis with Co Precipitation Volume 10, Research & Reviews: Journal of Pharmaceutics and Nanotechnology e-ISSN: 2347-7857 P-ISSN: 2347-7849.
68. Choudhary, F.; Naikoo, U.M.; Rizwan, A.; Kaur, J.; Abdin, M.Z.; Farooqi, H. Innovation in Lung Cancer Management from Herbal Nanomedicine to Artificial Intelligence. J. Nanotheranostics 2025, 6, 19.
69. Zhong, S.; Yao, S.; Zhao, Q.;Wang, Z.; Liu, Z.; Li, L.;Wang, Z.L. Electricity-Assisted Cancer Therapy: From Traditional Clinic Applications to Emerging Methods Integrated with Nanotechnologies. Adv. NanoBiomed Res. 2023, 3, 2200143.
70. Xin, Y.L.; Xue, F.Z.; Ge, B.S.; Zhao, F.R.; Shi, B.; Zhang,W. Electrochemical treatment of lung cancer. Bioelectromagn. J. Bioelectromagn. Soc. Soc. Phys. Regul. Biol. Med. Eur. Bioelectromagn. Assoc. 1997, 18, 8–13.
71. Zhu L, Zhang J, Guo Q, Kuang J, Li D, Wu M, Mo Y, Zhang T, Gao X and Tan J (2023), advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review Front. Bioeng. Biotechnol. 11:1299033.
72. Cusumano, G.; Calabrese, G.; Gallina, F.T.; Facciolo, F.; Novellis, P.; Veronesi, G.; Viscardi, S.; Lococo, F.; Meacci, E.; Terminella, A.; et al. Technical Innovations and Complex Cases in Robotic Surgery for Lung Cancer: A Narrative Review. Curr. Oncol. 2025, 32, 244.
73. Abeygunawaradana, P.; Gamage, N.; De Alwis, L.; Ashan, S.; Nilanka, C.; Godamune, P. E-Medic–Autonomous Drone for Healthcare System. In 2021 International Conference on Computing, Communication, and Intelligent Systems (ICCCIS); IEEE: Greater Noida, India, 2021; pp. 994–999.
74. Huang, D.; Li, Z.; Jiang, T.; Yang, C.; Li, N. Artificial intelligence in lung cancer: Current applications, future perspectives, and challenges. Front. Oncol. 2024, 14, 1486310.
75. Hamza Ahmed Qureshi1, Yahya Abdul Rehman Shah2, Sara Muddassir Qureshi3, Saad Ur Rehman Shah4, Ashish Shiwlani5, Ahsan Ahmad The Promising Role of Artificial Intelligence in Navigating Lung Cancer Prognosis International Journal for Multidisciplinary Research Volume 6 E-ISSN: 2582-2160

 

 

 

 

Ahead of Print Subscription Review Article
Volume 16
02
Received 08/04/2026
Accepted 28/04/2026
Published 02/05/2026
Publication Time 24 Days
58

Login


My IP

PlumX Metrics